



**SUBSCRIBE OR RENEW**  
Includes NEJM iPad Edition, 20 FREE  
Online CME Exams and more >>



- HOME
- ARTICLES & MULTIMEDIA ▾
- ISSUES ▾
- SPECIALTIES & TOPICS ▾
- FOR AUTHORS ▾
- CME >

Keyword, Title, Author, or Citation [Advanced Search >](#)

ORIGINAL ARTICLE

# Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

Paul M Ridker, M.D., Eleanor Danielson, M.I.A., Francisco A.H. Fonseca, M.D., Jacques Genest, M.D., Antonio M. Gotto, Jr., M.D., John J.P. Kastelein, M.D., Wolfgang Koenig, M.D., Peter Libby, M.D., Alberto J. Lorenzatti, M.D., Jean G. MacFadyen, B.A., Børge G. Nordestgaard, M.D., James Shepherd, M.D., James T. Willerson, M.D., and Robert J. Glynn, Sc.D., for the JUPITER Study Group  
N Engl J Med 2008; 359:2195-2207 | November 20, 2008 | DOI: 10.1056/NEJMoa0807646

Share:

**TOOLS**

- PDF
- Print
- Download Citation
- Supplementary Material
- E-Mail
- Save
- Article Alert
- Reprints
- Permissions
- Share/Bookmark

**RELATED ARTICLES**

**EDITORIAL**  
Expanding the Orbit of Primary Prevention — Moving beyond JUPITER  
November 20, 2008 | M.A. Hlatky

**EDITORIAL**  
JUPITER Clinical Directions — Polling Results  
March 5, 2009 | P. Kritek and E.W. Campion

**CORRESPONDENCE**  
Rosuvastatin in Patients with Elevated C-Reactive Protein  
March 5, 2009

**TOPICS**

- [Cardiology >](#)
- [Lipids >](#)
- [Coronary Disease/Myocardial Infarction >](#)
- [Diabetes >](#)
- [Stroke >](#)
- [Neuromuscular Disease >](#)

**MORE IN**

- [Research >](#)
- [November 20, 2008 >](#)

ADVERTISEMENT

**Chapter 2:**  
**How to Avoid Burning Out**  
and other benefits >

locumstory.com

**TRENDS**  
**Most Viewed (Last Week)**

- Abstract
- Article
- References
- Citing Articles (2119)
- Letters

**BACKGROUND**

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment.

[Full Text of Background...](#)

**METHODS**

We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.

[Full Text of Methods...](#)

**RESULTS**


The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes.

**MEDIA IN THIS ARTICLE**


**Poll Results**



**Contributors**




**FIGURE 1**



Cumulative Incidence of Cardiovascular Events According to Study Group.

**FIGURE 2**



Effects of Rosuvastatin on the Primary End Point, According to Baseline Characteristics.

**ARTICLE ACTIVITY**

[Full Text of Results...](#)

## CONCLUSIONS

In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, [NCT00239681](#).)

[Full Text of Discussion...](#)

[Read the Full Article...](#)

2119 articles have cited  
this article [»](#)

### IMAGES IN CLINICAL MEDICINE

Cullen's and Grey Turner's Signs in Acute Pancreatitis [47,253 views]

December 10, 2015 | X. Valette and D.D. Cheyron

### EDITORIAL

Leading the Transformation of Health Care Delivery — The Launch of NEJM Catalyst [31,468 views]

December 17, 2015 | T.H. Lee and Others

### CLINICAL PRACTICE

Thyroid Nodules [23,671 views]

December 10, 2015 | K.D. Burman and L. Wartofsky

[More Trends »](#)

## NEJM CareerCenter

### PHYSICIAN JOBS

December 17, 2015

#### Chiefs/Directors/Dept. Heads

[Vice President, Oncology Service Line and Deputy Director, Norris Cotton Cancer Center](#)  
NEW HAMPSHIRE

#### Family Medicine

[Family Medicine Physician](#)  
NORTH CAROLINA

#### Faculty

[CLINICIAN INVESTIGATOR](#)  
PENNSYLVANIA

#### Internal Medicine

[Post Acute Physician](#)  
MASSACHUSETTS

#### Surgery, Neurological

[Neurosurgeon – Billings, Montana](#)  
MONTANA

#### General Practice

[Texas -Near Houston & Austin-Outpatient Only FP](#)  
TEXAS

[nejmcareercenter.org](#)



**Sign up for FREE »**  
**Alerts and Updates**

## NEJM Catalyst

Discover practical ways  
to successfully  
implement change today

**GET STARTED**

**CONTENT:** [Home](#) | [Current Issue](#) | [Articles](#) | [Issue Index](#) | [Specialties & Topics](#) | [Multimedia & Images](#) | [Archive 1812-1989](#)

**INFORMATION FOR:** [Authors](#) | [Reviewers](#) | [Subscribers](#) | [Institutions](#) | [Media](#) | [Advertisers](#)

**SERVICES:** [Subscribe](#) | [Renew](#) | [Pay Bill](#) | [Activate Subscription](#) | [Create or Manage Account](#) | [Alerts](#) | [RSS & Podcasts](#) | [Submit a Manuscript](#) | [Mobile](#)

**RESOURCES:** [Physician Jobs](#) | [Reprints](#) | [Permissions](#) | [Medical Meetings](#) | [Conventions](#) | [FAQs](#) | [NEJM Knowledge+](#) | [NEJM Journal Watch](#) | [Help](#) | [Contact Us](#)

**NEJM:** [About](#) | [Product Information](#) | [Editors & Publishers](#) | [200th Anniversary](#) | [Terms of Use](#) | [Privacy Policy](#) | [Copyright](#) | [Advertising Policies](#) | [NEJM Group](#)

**CME:** [Weekly CME Program](#) | [Browse Weekly Exams](#) | [Your CME Activity](#) | [Purchase Exams](#) | [Review CME Program](#)

**Earn CME Credits »**  
Over 300 exams available

Follow us

